| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
|
N Engl J Med
|
2015
|
10.86
|
|
2
|
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
|
N Engl J Med
|
2008
|
6.32
|
|
3
|
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
|
Ann Intern Med
|
2010
|
5.79
|
|
4
|
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
|
N Engl J Med
|
2012
|
5.25
|
|
5
|
Perioperative management of patients receiving oral anticoagulants: a systematic review.
|
Arch Intern Med
|
2003
|
5.02
|
|
6
|
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
|
Lancet
|
2002
|
4.21
|
|
7
|
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
|
Circulation
|
2004
|
3.83
|
|
8
|
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
|
BMJ
|
2006
|
3.58
|
|
9
|
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.
|
Arch Intern Med
|
2004
|
2.34
|
|
10
|
Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.
|
Chest
|
2007
|
2.32
|
|
11
|
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature.
|
Circulation
|
2012
|
2.16
|
|
12
|
Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.
|
PLoS One
|
2013
|
1.97
|
|
13
|
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.
|
Chest
|
2010
|
1.67
|
|
14
|
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
|
Arch Intern Med
|
2005
|
1.64
|
|
15
|
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.
|
Thromb Res
|
2006
|
1.48
|
|
16
|
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
|
Thromb Haemost
|
2010
|
1.47
|
|
17
|
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?
|
Br J Haematol
|
2009
|
1.46
|
|
18
|
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions.
|
Am Heart J
|
2006
|
1.41
|
|
19
|
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
|
Clin Pharmacokinet
|
2008
|
1.39
|
|
20
|
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients.
|
Thromb Haemost
|
2005
|
1.27
|
|
21
|
The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines.
|
Can J Cardiol
|
2011
|
1.25
|
|
22
|
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).
|
Am Heart J
|
2011
|
1.20
|
|
23
|
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients.
|
Thromb Haemost
|
2005
|
1.19
|
|
24
|
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.
|
Blood Coagul Fibrinolysis
|
2003
|
1.08
|
|
25
|
Surgical management of valvular heart disease 2004.
|
Can J Cardiol
|
2004
|
0.99
|
|
26
|
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.
|
Blood
|
2010
|
0.97
|
|
27
|
Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trial.
|
J Stroke Cerebrovasc Dis
|
2007
|
0.87
|
|
28
|
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
|
Thromb Haemost
|
2007
|
0.87
|
|
29
|
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.
|
Arch Pathol Lab Med
|
2004
|
0.86
|
|
30
|
The safety of antithrombotic therapy during pregnancy.
|
Expert Opin Drug Saf
|
2004
|
0.85
|
|
31
|
Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry).
|
Am J Cardiol
|
2008
|
0.84
|
|
32
|
Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery.
|
J Arthroplasty
|
2006
|
0.84
|
|
33
|
New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.
|
CMAJ
|
2002
|
0.83
|
|
34
|
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
|
J Am Coll Cardiol
|
2008
|
0.81
|
|
35
|
Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.
|
Thromb Haemost
|
2012
|
0.81
|
|
36
|
Valvar heart disease and prosthetic heart valves.
|
BMJ
|
2002
|
0.80
|
|
37
|
Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?
|
Can Fam Physician
|
2007
|
0.80
|
|
38
|
Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.
|
J Thromb Thrombolysis
|
2006
|
0.80
|
|
39
|
Prevention of venous thromboembolism among hospitalized medical patients.
|
Circulation
|
2005
|
0.79
|
|
40
|
Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns.
|
CMAJ
|
2008
|
0.79
|
|
41
|
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
|
Vasc Med
|
2007
|
0.78
|
|
42
|
Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.
|
Ann Surg
|
2014
|
0.78
|
|
43
|
Venous thromboembolism management: where do novel anticoagulants fit?
|
Curr Med Res Opin
|
2013
|
0.77
|
|
44
|
Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy.
|
Circulation
|
2003
|
0.77
|
|
45
|
The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients.
|
Am Heart J
|
2005
|
0.77
|
|
46
|
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
|
Thromb Haemost
|
2013
|
0.76
|
|
47
|
Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation.
|
Curr Opin Pulm Med
|
2005
|
0.76
|
|
48
|
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery.
|
Lancet
|
2003
|
0.75
|
|
49
|
Multidetector-row computed tomography in suspected pulmonary embolism.
|
N Engl J Med
|
2005
|
0.75
|
|
50
|
Response to "Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban".
|
J Clin Pharmacol
|
2011
|
0.75
|
|
51
|
What's new for DVT prophylaxis for the medically ill.
|
Dis Mon
|
2005
|
0.75
|
|
52
|
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
|
Thromb Haemost
|
2017
|
0.75
|
|
53
|
Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST).
|
J Neurol Sci
|
2007
|
0.75
|
|
54
|
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
|
Clin Cornerstone
|
2005
|
0.75
|
|
55
|
Spotlight on real-world evidence for the treatment of DVT: XALIA.
|
Thromb Haemost
|
2016
|
0.75
|
|
56
|
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
|
Thromb Haemost
|
2016
|
0.75
|
|
57
|
Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
|
Thromb Haemost
|
2016
|
0.75
|
|
58
|
Drug reimbursement policies in Canada--need for improved access to critical therapies.
|
Ann Pharmacother
|
2008
|
0.75
|
|
59
|
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist.
|
J South Orthop Assoc
|
2002
|
0.75
|
|
60
|
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
|
Curr Opin Pulm Med
|
2002
|
0.75
|
|
61
|
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
|
Thromb Haemost
|
2013
|
0.75
|